• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

家族性高胆固醇血症的检测:FAMCAT 临床病例发现算法在初级保健中识别患者的外部验证。

Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care.

机构信息

Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of Nottingham, Nottingham, UK.

Primary Care Stratified Medicine (PRISM), Division of Primary Care, University of Nottingham, Nottingham, UK.

出版信息

Lancet Public Health. 2019 May;4(5):e256-e264. doi: 10.1016/S2468-2667(19)30061-1.

DOI:10.1016/S2468-2667(19)30061-1
PMID:31054643
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6506568/
Abstract

BACKGROUND

The vast majority of individuals with familial hypercholesterolaemia in the general population remain unidentified worldwide. Recognising patients most likely to have the condition, to enable targeted specialist assessment and treatment, could prevent major coronary morbidity and mortality. We aimed to evaluate a clinical case-finding algorithm, the familial hypercholesterolaemia case ascertainment tool (FAMCAT), and compare it with currently recommended methods for detection of familial hypercholesterolaemia in primary care.

METHODS

In this external validation study, FAMCAT regression equations were applied to a retrospective cohort of patients aged 16 years or older with cholesterol assessed, who were randomly selected from 1500 primary care practices across the UK contributing to the QResearch database. In the main analysis, we assessed the ability of FAMCAT to detect familial hypercholesterolaemia (ie, its discrimination) and compared it with that of other established clinical case-finding approaches recommended internationally (Simon Broome, Dutch Lipid Clinic Network, Make Early Diagnosis to Prevent Early Deaths [MEDPED] and cholesterol concentrations higher than the 99th percentile of the general population in the UK). We assessed discrimination by area under the receiver operating curve (AUROC; ranging from 0·5, indicating pure chance, to 1, indicating perfect discrimination). Using a probability threshold of more than 1 in 500 (prevalence of familial hypercholesterolaemia), we also assessed sensitivity, specificity, positive predictive values, and negative predictive values in the main analysis.

FINDINGS

A sample of 750 000 patients who registered in 1500 UK primary care practices that contribute anonymised data to the QResearch database between Jan 1, 1999, and Sept 1, 2017, was randomly selected, of which 747 000 patients were assessed. FAMCAT showed a high degree of discrimination (AUROC 0·832, 95% CI 0·820-0·845), which was higher than that of Simon Broome criteria (0·694, 0·681-0·703), Dutch Lipid Clinic Network criteria (0·724, 0·710-0·738), MEDPED criteria (0·624, 0·609-0·638), and screening cholesterol concentrations higher than the 99th percentile (0·581, 0·570-0·591). Using a 1 in 500 probability threshold, FAMCAT achieved a sensitivity of 84% (1028 predicted vs 1219 observed cases) and specificity of 60% (443 949 predicted vs 745 781 observed non-cases), with a corresponding positive predictive value of 0·84% and a negative predictive value of 99·2%.

INTERPRETATION

FAMCAT identifies familial hypercholesterolaemia with greater accuracy than currently recommended approaches and could be considered for clinical case finding of patients with the highest likelihood of having hypercholesterolaemia in primary care.

FUNDING

UK National Institute for Health Research School for Primary Care Research.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ff/6506568/0386414387d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ff/6506568/1c1a63199563/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ff/6506568/0386414387d0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ff/6506568/1c1a63199563/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46ff/6506568/0386414387d0/gr2.jpg
摘要

背景

在全球范围内,绝大多数普通人群中的家族性高胆固醇血症患者尚未被发现。识别出最有可能患有该疾病的患者,以便进行有针对性的专家评估和治疗,可预防主要的冠状动脉发病率和死亡率。我们旨在评估一种临床病例发现算法,即家族性高胆固醇血症病例确定工具(FAMCAT),并将其与目前在初级保健中用于检测家族性高胆固醇血症的推荐方法进行比较。

方法

在这项外部验证研究中,将 FAMCAT 回归方程应用于从参与 QResearch 数据库的英国 1500 个初级保健实践中随机选择的年龄在 16 岁或以上且胆固醇水平已评估的患者的回顾性队列中。在主要分析中,我们评估了 FAMCAT 检测家族性高胆固醇血症(即其判别能力)的能力,并将其与国际上推荐的其他既定临床病例发现方法(Simon Broome、荷兰脂质诊所网络、早期诊断以预防早期死亡[MEDPED]和胆固醇浓度高于英国普通人群的第 99 百分位)进行了比较。我们通过接受者操作特征曲线下的面积(AUROC;范围从 0.5,指示纯机会,到 1,指示完美的判别)来评估判别能力。使用大于 1/500(家族性高胆固醇血症的患病率)的概率阈值,我们还在主要分析中评估了敏感性、特异性、阳性预测值和阴性预测值。

结果

从 1999 年 1 月 1 日至 2017 年 9 月 1 日在 QResearch 数据库中注册的 1500 个英国初级保健实践中随机选择了一个样本量为 750 万患者的队列,对其中的 747 万患者进行了评估。FAMCAT 表现出高度的判别能力(AUROC 0.832,95%CI 0.820-0.845),高于 Simon Broome 标准(0.694,0.681-0.703)、荷兰脂质诊所网络标准(0.724,0.710-0.738)、MEDPED 标准(0.624,0.609-0.638)和胆固醇浓度高于第 99 百分位(0.581,0.570-0.591)。使用 1/500 的概率阈值,FAMCAT 实现了 84%的敏感性(1028 例预测 vs 1219 例观察病例)和 60%的特异性(443949 例预测 vs 745781 例观察非病例),相应的阳性预测值为 0.84%,阴性预测值为 99.2%。

解释

FAMCAT 比目前推荐的方法更准确地识别家族性高胆固醇血症,可考虑用于初级保健中具有高胆固醇血症可能性的患者的临床病例发现。

资金

英国国家健康研究所初级保健研究学院。

相似文献

1
Detection of familial hypercholesterolaemia: external validation of the FAMCAT clinical case-finding algorithm to identify patients in primary care.家族性高胆固醇血症的检测:FAMCAT 临床病例发现算法在初级保健中识别患者的外部验证。
Lancet Public Health. 2019 May;4(5):e256-e264. doi: 10.1016/S2468-2667(19)30061-1.
2
Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study.评估一种用于在初级保健中识别家族性高胆固醇血症的临床工具(FAMCAT):一项回顾性队列研究。
BJGP Open. 2020 Dec 15;4(5). doi: 10.3399/bjgpopen20X101114. Print 2020 Dec.
3
Comparing the performance of the novel FAMCAT algorithms and established case-finding criteria for familial hypercholesterolaemia in primary care.比较新型 FAMCAT 算法与初级保健中家族性高胆固醇血症既定病例发现标准的性能。
Open Heart. 2021 Oct;8(2). doi: 10.1136/openhrt-2021-001752.
4
Improving identification of familial hypercholesterolaemia in primary care: derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).改善初级保健中家族性高胆固醇血症的识别:家族性高胆固醇血症病例确定工具(FAMCAT)的推导与验证
Atherosclerosis. 2015 Feb;238(2):336-43. doi: 10.1016/j.atherosclerosis.2014.12.034. Epub 2014 Dec 20.
5
High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.高脂蛋白(a)作为临床家族性高胆固醇血症的可能病因:一项前瞻性队列研究。
Lancet Diabetes Endocrinol. 2016 Jul;4(7):577-87. doi: 10.1016/S2213-8587(16)30042-0. Epub 2016 May 13.
6
Electronic health record-based facilitation of familial hypercholesterolaemia detection sensitivity of different algorithms in genetically confirmed patients.基于电子健康记录促进家族性高胆固醇血症检测:不同算法在基因确诊患者中的敏感性
Eur Heart J Digit Health. 2022 Oct 17;3(4):578-586. doi: 10.1093/ehjdh/ztac059. eCollection 2022 Dec.
7
Diagnostic performance of various familial hypercholesterolaemia diagnostic criteria compared to Dutch lipid clinic criteria in an Asian population.在亚洲人群中,将各种家族性高胆固醇血症诊断标准与荷兰脂质诊所标准相比较的诊断性能。
BMC Cardiovasc Disord. 2017 Oct 16;17(1):264. doi: 10.1186/s12872-017-0694-z.
8
Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study.使用家族性高胆固醇血症病例确定工具(FAMCAT)早期识别家族性高胆固醇血症以降低马来西亚的早发性冠状动脉疾病:一项混合方法评估研究方案
JMIR Res Protoc. 2023 Jun 2;12:e47911. doi: 10.2196/47911.
9
Strategies for screening for familial hypercholesterolaemia in primary care and other community settings.在初级保健和其他社区环境中筛查家族性高胆固醇血症的策略。
Cochrane Database Syst Rev. 2021 Oct 7;10(10):CD012985. doi: 10.1002/14651858.CD012985.pub2.
10
Clinical and genetic diagnosis of familial hypercholesterolaemia in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study.接受冠状动脉造影患者家族性高胆固醇血症的临床与基因诊断:路德维希港风险与心血管健康研究
Eur Heart J Qual Care Clin Outcomes. 2024 Nov 5;10(7):632-640. doi: 10.1093/ehjqcco/qcad075.

引用本文的文献

1
EHR-Based Screening of Familial Hypercholesterolemia: Finding the Lipid in the Haystack.基于电子健康记录筛查家族性高胆固醇血症:大海捞针找血脂
JACC Adv. 2024 Oct 16;3(12):101296. doi: 10.1016/j.jacadv.2024.101296. eCollection 2024 Dec.
2
A case report of heterozygous familial hypercholesterolaemia with gene mutation complicated by premature coronary artery disease detected in primary care.基层医疗中检测到的一例杂合子家族性高胆固醇血症伴基因突变并合并早发性冠状动脉疾病的病例报告。
Eur Heart J Case Rep. 2024 Jan 29;8(2):ytae039. doi: 10.1093/ehjcr/ytae039. eCollection 2024 Feb.
3
A comparative study of explainable ensemble learning and logistic regression for predicting in-hospital mortality in the emergency department.

本文引用的文献

1
Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.在初级保健中筛查家族性高胆固醇血症:是时候让全科医生发挥作用了。
Atherosclerosis. 2018 Oct;277:399-406. doi: 10.1016/j.atherosclerosis.2018.08.019.
2
A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.家族性高胆固醇血症突变表型预测因子的比较分析。
J Clin Endocrinol Metab. 2018 Apr 1;103(4):1704-1714. doi: 10.1210/jc.2017-02622.
3
Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis.
一种用于预测急诊科住院死亡率的可解释集成学习与逻辑回归的对比研究。
Sci Rep. 2024 Feb 10;14(1):3406. doi: 10.1038/s41598-024-54038-4.
4
Case Series of Genetically Confirmed Index Cases of Familial Hypercholesterolemia in Primary Care.原发性医护中经基因确认的家族性高胆固醇血症家系索引病例的病例系列。
Am J Case Rep. 2023 Apr 27;24:e939489. doi: 10.12659/AJCR.939489.
5
Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study.使用家族性高胆固醇血症病例确定工具(FAMCAT)早期识别家族性高胆固醇血症以降低马来西亚的早发性冠状动脉疾病:一项混合方法评估研究方案
JMIR Res Protoc. 2023 Jun 2;12:e47911. doi: 10.2196/47911.
6
Electronic health record-based facilitation of familial hypercholesterolaemia detection sensitivity of different algorithms in genetically confirmed patients.基于电子健康记录促进家族性高胆固醇血症检测:不同算法在基因确诊患者中的敏感性
Eur Heart J Digit Health. 2022 Oct 17;3(4):578-586. doi: 10.1093/ehjdh/ztac059. eCollection 2022 Dec.
7
Role of an automated screening tool for familial hypercholesterolemia in patients with premature coronary artery disease.一种用于家族性高胆固醇血症的自动筛查工具在早发性冠状动脉疾病患者中的作用。
Atheroscler Plus. 2022 Jan 6;48:1-7. doi: 10.1016/j.athplu.2022.01.001. eCollection 2022 Apr.
8
Improvement of Definite Diagnosis of Familial Hypercholesterolemia Using an Expanding Genetic Analysis.通过扩展基因分析改善家族性高胆固醇血症的明确诊断
JACC Asia. 2021 Apr 21;1(1):82-89. doi: 10.1016/j.jacasi.2021.04.001. eCollection 2021 Jun.
9
Developing a Hybrid Risk Assessment Tool for Familial Hypercholesterolemia: A Machine Learning Study of Chinese Arteriosclerotic Cardiovascular Disease Patients.开发一种用于家族性高胆固醇血症的混合风险评估工具:一项针对中国动脉粥样硬化性心血管疾病患者的机器学习研究。
Front Cardiovasc Med. 2022 Aug 3;9:893986. doi: 10.3389/fcvm.2022.893986. eCollection 2022.
10
Comparative study on the performance of different classification algorithms, combined with pre- and post-processing techniques to handle imbalanced data, in the diagnosis of adult patients with familial hypercholesterolemia.不同分类算法性能的对比研究,结合预处理和后处理技术来处理不平衡数据,在诊断成年家族性高胆固醇血症患者中的应用。
PLoS One. 2022 Jun 24;17(6):e0269713. doi: 10.1371/journal.pone.0269713. eCollection 2022.
估计杂合子家族性高胆固醇血症的患病率:一项系统评价和荟萃分析。
BMJ Open. 2017 Sep 1;7(9):e016461. doi: 10.1136/bmjopen-2017-016461.
4
Development and validation of risk prediction equations to estimate survival in patients with colorectal cancer: cohort study.用于估计结直肠癌患者生存率的风险预测方程的开发与验证:队列研究
BMJ. 2017 Jun 15;357:j2497. doi: 10.1136/bmj.j2497.
5
Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.用于估计心血管疾病未来风险的QRISK3风险预测算法的开发与验证:前瞻性队列研究
BMJ. 2017 May 23;357:j2099. doi: 10.1136/bmj.j2099.
6
Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.基于英国家族性高胆固醇血症服务机构的数据,对家族性高胆固醇血症的级联检测的成本效益进行评估。
Eur Heart J. 2017 Jun 14;38(23):1832-1839. doi: 10.1093/eurheartj/ehx111.
7
Child-Parent Familial Hypercholesterolemia Screening in Primary Care.儿童-父母家族性高胆固醇血症的初级保健筛查。
N Engl J Med. 2016 Oct 27;375(17):1628-1637. doi: 10.1056/NEJMoa1602777.
8
Rapid identification of familial hypercholesterolemia from electronic health records: The SEARCH study.从电子健康记录中快速识别家族性高胆固醇血症:SEARCH 研究。
J Clin Lipidol. 2016 Sep-Oct;10(5):1230-9. doi: 10.1016/j.jacl.2016.08.001. Epub 2016 Aug 6.
9
Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study.在全科医疗中改善家族性高胆固醇血症识别的可行性:干预措施开发研究
BMJ Open. 2016 May 26;6(5):e011734. doi: 10.1136/bmjopen-2016-011734.
10
Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia.家族性高胆固醇血症患者遗传检测的选择:导致家族性高胆固醇血症突变的存在预测模型的建立和外部验证。
Eur Heart J. 2017 Feb 21;38(8):565-573. doi: 10.1093/eurheartj/ehw135.